LGVN (longeveron.com) Enterprise Value-to-Revenue Ratio

Longeveron (LGVN) - corporate logo

The enterprise value-to-revenue multiple confirms the high reputation of Longeveron Inc. (LGVN) in regenerative medicine due to the development of safe Alzheimer's treatments, where -598.29 represents the current metric level. Innovations in cellular tissue restoration for longevity combine with investor confidence in the updated management following the publication of successful clinical results.

Longeveron Corporation (LGVN): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/20/2026

LGVN (Longeveron Inc.): analytical breakdowns and indicator data

- price and consensus price forecast:
- business market valuation indicators:
Fundamental valuation:Longeveron Inc. LGVN
Core merchandise of Longeveron Corporation

Longeveron Inc. utilizes its own drug production laboratories to minimize external costs, which directly impacts the dynamics of the enterprise value-to-annual revenue multiple. This indicator compares market capitalization, adjusted for net debt, against sales volume, allowing investors to assess the fairness of the current business valuation; however, abnormally low values may signal fundamental risks or a "value trap."